Document is current
Any future updates will be listed below
-
Authors
Faergeman, Søren L. https://orcid.org/0000-0002-4482-1578
Andreasen, Lotte
Becher, Naja
Christiansen, Mette https://orcid.org/0000-0001-5158-3670
Gravholt, Claus H. https://orcid.org/0000-0001-5924-1720
Jensen, Uffe B. https://orcid.org/0000-0002-6205-6355
Jensen, Jens Magnus Bernth https://orcid.org/0000-0002-5004-7822
Larsen, Ole H.
Markholt, Sara
Sandgaard, Katrine S.
Vang, Søren https://orcid.org/0000-0002-1899-4205
Lildballe, Dorte L. https://orcid.org/0000-0003-0223-1673
-
Funding
Funding for this research was provided by:
Health Research Fund of Central Denmark Region
Aase og Ejnar Danielsens Fond
A.P. Møller Fonden | Fonden til Lægevidenskabens Fremme
- License Information
-
More Information
Article History
Received: 22 August 2025
Revised: 22 December 2025
Accepted: 11 March 2026
First Online: 31 March 2026
Competing interests
: DL, SLF, JMBJ, NB, MC, KSS, LA, SM, UBJ, and SV. CHG (has received honorariums for scientific talks from Novo Nordisk, Merck and Astra-Zeneca) OHL (has received honorariums for scientific talks from Illumina).
: The Scientific Ethics Committee of the Central Denmark Region evaluated the study and determined that it did not require ethics approval (case 1-10-72-103-24). The study was approved as a quality project by the hospital management at Aarhus University Hospital, Aarhus, Denmark.
